PortalPublikationenHypothalamo-pituitary-adrenal axis activity predicts disease...

Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.

Standard

Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. / Gold, Stefan M; Raji, Alaleh; Huitinga, Inge; Wiedemann, Klaus; Schulz, Karl-Heinz; Heesen, Christoph.

in: J NEUROIMMUNOL, Jahrgang 165, Nr. 1-2, 1-2, 2005, S. 186-191.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gold, SM, Raji, A, Huitinga, I, Wiedemann, K, Schulz, K-H & Heesen, C 2005, 'Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.', J NEUROIMMUNOL, Jg. 165, Nr. 1-2, 1-2, S. 186-191. <http://www.ncbi.nlm.nih.gov/pubmed/15935481?dopt=Citation>

APA

Gold, S. M., Raji, A., Huitinga, I., Wiedemann, K., Schulz, K-H., & Heesen, C. (2005). Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. J NEUROIMMUNOL, 165(1-2), 186-191. [1-2]. http://www.ncbi.nlm.nih.gov/pubmed/15935481?dopt=Citation

Vancouver

Gold SM, Raji A, Huitinga I, Wiedemann K, Schulz K-H, Heesen C. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. J NEUROIMMUNOL. 2005;165(1-2):186-191. 1-2.

Bibtex

@article{0ec853c2b4a74087b65acc1427000dee,
title = "Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.",
abstract = "Clinical studies have shown that groups of multiple sclerosis (MS) patients exhibit a chronically activated hypothalamo-pituitary-adrenal (HPA) axis. However, the association of HPA axis activity and disease progression in MS is unknown. In this longitudinal study over a 3-year follow-up period, we report that patients who exhibited stronger HPA reactivity at baseline were significantly more likely to experience progression as measured by the Expanded Disability Status Scale (EDSS) during the follow-up period. Furthermore, HPA axis activity correlated with progression ratings and cognitive impairment three years later. Tests of HPA axis activity may be useful biomarkers for disease progression in MS.",
author = "Gold, {Stefan M} and Alaleh Raji and Inge Huitinga and Klaus Wiedemann and Karl-Heinz Schulz and Christoph Heesen",
year = "2005",
language = "Deutsch",
volume = "165",
pages = "186--191",
journal = "J NEUROIMMUNOL",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

RIS

TY - JOUR

T1 - Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.

AU - Gold, Stefan M

AU - Raji, Alaleh

AU - Huitinga, Inge

AU - Wiedemann, Klaus

AU - Schulz, Karl-Heinz

AU - Heesen, Christoph

PY - 2005

Y1 - 2005

N2 - Clinical studies have shown that groups of multiple sclerosis (MS) patients exhibit a chronically activated hypothalamo-pituitary-adrenal (HPA) axis. However, the association of HPA axis activity and disease progression in MS is unknown. In this longitudinal study over a 3-year follow-up period, we report that patients who exhibited stronger HPA reactivity at baseline were significantly more likely to experience progression as measured by the Expanded Disability Status Scale (EDSS) during the follow-up period. Furthermore, HPA axis activity correlated with progression ratings and cognitive impairment three years later. Tests of HPA axis activity may be useful biomarkers for disease progression in MS.

AB - Clinical studies have shown that groups of multiple sclerosis (MS) patients exhibit a chronically activated hypothalamo-pituitary-adrenal (HPA) axis. However, the association of HPA axis activity and disease progression in MS is unknown. In this longitudinal study over a 3-year follow-up period, we report that patients who exhibited stronger HPA reactivity at baseline were significantly more likely to experience progression as measured by the Expanded Disability Status Scale (EDSS) during the follow-up period. Furthermore, HPA axis activity correlated with progression ratings and cognitive impairment three years later. Tests of HPA axis activity may be useful biomarkers for disease progression in MS.

M3 - SCORING: Zeitschriftenaufsatz

VL - 165

SP - 186

EP - 191

JO - J NEUROIMMUNOL

JF - J NEUROIMMUNOL

SN - 0165-5728

IS - 1-2

M1 - 1-2

ER -